The European clinical trial databases, which are maintained by the regulators, not the company, showed approval in October 2020. It takes a process of approval before then for it to show up then. Plus it was discussed by the company for 2 years previous and at that annual meeting just before in extensive detail.
Read the press release, there is nothing stating the SAP was being completely changed. It wasn't until the TLD was released that the recurrent GBM arm was announced.
In addition, the datalock is quickly followed by unblinding required for statisticians to do the preliminary TLD. The unblinding is a quick procedure as is the preliminary TLD with PFS and OS endpoints. NWBO would have to know the recurrent GBM sample size -- otherwise they couldn't commit to doing a rGBM arm. It was never part of the original trial protocol or SAP.
The name of the trial is: "Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer (GBM)"
Market Data 
Markets 
AI
